RT Dissertation/Thesis
T1 Nanoassemblies for the intracellular delivery of monoclonal antibodies in cancer therapy
A1 López Estévez, Ana María
K1 monoclonal antibodies
K1 cancer
K1 nanomedicine
K1 HANAs
K1 cancer therapeutics
AB Mutations in the Kirsten Rat Sarcoma Virus (KRAS) oncoproteinare particularly relevant therapeutic targets in lung cancer,among others. Although one KRAS mutation has beenaddressed, KRAS is still considered an undruggable target. Inthis scenario, monoclonal antibodies (mAbs) have emerged asthe main alternative to achieve a positive efficacy/toxicitybalance while blocking intracellular oncoproteins. Hence, wehave developed novel nanoassemblies (HANAs) for theintracellular delivery of mAbs and functionalized or not with thetumor penetrating peptide tLyP1. HANAs were evaluatedaccording to i) the capacity to load mAbs, ii) the ability tomodify the biodistribution profile of the mAb, and iii) theperformance in terms of activity and target engagementtowards the KRASG12V oncoprotein.
YR 2023
FD 2023
LK http://hdl.handle.net/10347/31286
UL http://hdl.handle.net/10347/31286
LA eng
DS Minerva
RD 24 abr 2026